Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, four children with recurrent atypical teratoid rhabdoid tumors experienced disease stabilization or regression after treatment with alisertib, suggesting its potential role in future trials for this condition.

In this study, tebentafusp-tebn improved overall survival in patients with metastatic uveal melanoma compared to standard therapies, despite higher rates of significant adverse events.

In this study, Ritlecitinib was reported as a newly approved treatment for alopecia areata that can be used in patients aged 12 and older; after 24 weeks, it resulted in 80% or more scalp hair coverage in treated patients compared to a placebo.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

This review examines dermatological side effects of taxane chemotherapy reported in past studies and highlights the necessity for identifying and managing these conditions to maintain cancer patients' quality of life; it presents no new clinical results.

This article reviews the effects of various medications on male fertility, noting that while commonly used drugs can mostly have reversible impacts, conclusive human evidence remains limited.

This review discusses the role of δ-subunit-containing GABA A receptors and neurosteroids in temporal lobe epilepsy, highlighting their plasticity and potential pharmacological implications, without reporting new clinical results.

Finasteride blocks progesterone's effect on absence seizures in rats.

In this study, finasteride-treated WAG/Rij rats showed a significant increase in spike-wave discharges when administered endogenous steroids THPROG and THDOC, indicating potential exacerbation of absence seizures.

This study emphasizes the necessity of confirming elevated testosterone levels detected by immunoassay with liquid chromatography-tandem mass spectroscopy before pursuing more complex diagnostic evaluations.

This study identified disproportionate reporting of several serious unknown or less documented adverse events associated with biologics for severe asthma, suggesting the need for further safety assessments.

This review examined the medicinal properties of the Ziziphus plant species, highlighting their traditional use in treating various conditions and their bioactive compounds with potential anticancer, antimicrobial, and anti-diabetic effects. The authors concluded that Ziziphus species, particularly jujube, have promising pharmacological activities warranting further investigation.

This study found that Si extract, cryptomeridiol, and SiAgNPs have the ability to induce cell death and prevent cell growth in HepG2 liver cancer cells, suggesting cryptomeridiol's potential as a phytochemical component in developing new therapies for hepatocellular carcinoma using nanotechnology in vitro.

This research explores if COVID-19, analogous to SARS-CoV, may result in long-term pulmonary fibrosis in recovered patients, although current evidence on the persistence or resolution of lung changes over time remains unknown.

This review suggests that injectable platelet-rich fibrin therapy shows promise for improving hair density in androgenetic alopecia and enhancing facial skin texture and elasticity, but larger studies are needed to confirm its effectiveness.

This case report suggests that systemic lupus erythematosus can be a rare cause of severe hypercalcemia, potentially due to stimulating parathyroid hormone receptor autoantibodies.

This study found that all examined biomarkers and clinical features were elevated in systemic lupus erythematosus patients, particularly ANA and Anti-dsDNA autoantibodies, but no single biomarker was sensitive or specific enough for diagnosis.

In this note, editors discuss the reproduction of medical content by Dr. Paul E. Marik, related to standardized coronavirus treatments, emphasizing that the materials appear effective and cautioning readers to consult their doctors for guidance.

This study reported that ritlecitinib 50 mg and baricitinib 4 mg showed similar efficacy in treating severe alopecia areata, with no significant difference in hair regrowth outcomes at Week 24, but there remains considerable uncertainty and a need for further research.

This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.

This study reviewed evidence on eribulin's efficacy and safety for treating metastatic triple-negative breast cancer, highlighting variable survival outcomes and manageable safety profiles for both monotherapy and combination therapies.

In this study, researchers found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg at both 24 and 52 weeks for treating severe alopecia areata, suggesting potential implications for reimbursement or formulary decisions.

CTP-543 is generally safe for treating alopecia areata.

This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.

This study reports that long-term treatment with ritlecitinib is generally well tolerated for up to approximately five years in patients aged 12 and older with alopecia areata, with the safety profile aligning with previous data from the ALLEGRO clinical trials.

This study reported that patients with alopecia areata treated with ritlecitinib in a real-life setting had a higher rate of positive response on the Severity of Alopecia Tool score compared to those in the ALLEGRO trial.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

This study found that 45.5% of alopecia areata patients treated with ritlecitinib 50 mg daily achieved significant hair regrowth, with most maintaining their response over 24 months.